



























- and predicts response to mTORC1 inhibitor everolimus. *Mol Cancer Ther* 2015;14:1224-35.
45. Zhang Y, Ng PK, Kucherlapati M, Chen F, Liu Y, et al. A pan-cancer proteogenomic atlas of PI3K/AKT/mTOR pathway alterations. *Cancer Cell* 2017;31:820-32.
  46. Grabiner BC, Nardi V, Birsoy K, Possemato R, Shen K, et al. A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity. *Cancer Discov* 2014;4:554-63.
  47. Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangiomyomatosis. *N Engl J Med* 2008;358:140-51.
  48. Davies DM, de Vries PJ, Johnson SR, McCartney DL, Cox JA, et al. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangiomyomatosis: a phase 2 trial. *Clin Cancer Res* 2011;17:4071-81.
  49. Cabrera López C, Martí T, Catalá V, Torres F, Mateu S, et al. Effects of rapamycin on angiomyolipomas in patients with tuberous sclerosis. *Nefrologia* 2011;31:292-8.
  50. Krueger DA, Care MM, Holland K, Agricola K, Tudor C, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. *N Engl J Med* 2010;363:1801-11.
  51. Dabora SL, Franz DN, Ashwal S, Sagalowsky A, DiMario FJ Jr, et al. Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease. *PLoS One* 2011;6:e23379.
  52. Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. *Lancet* 2013;381:125-32.
  53. Saffari A, Brosse I, Wiemer-Kriel A, Wilken B, Kreuzaler P, et al. Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age - a multicenter retrospective study. *Orphanet J Rare Dis* 2019;14:96.
  54. Pantuck AJ, Seligson DB, Klatte T, Yu H, Leppert JT, et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. *Cancer* 2007;109:2257-67.
  55. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, et al; RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. *Lancet* 2008;372:449-56.
  56. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, et al; RECORD-1 Study Group. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. *Cancer* 2010;116:4256-65.
  57. Stein A, Bellmunt J, Escudier B, Kim D, Stergiopoulos SG, et al; RECORD-1 Trial Study Group. Survival prediction in everolimus-treated patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial. *Eur Urol* 2013;64:994-1002.
  58. Escudier B, Molinie V, Bracarda S, Maroto P, Szczylik C, et al. Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis. *Eur J Cancer* 2016;69:226-35.
  59. Missiaglia E, Dalai I, Barbi S, Beghelli S, Falconi M, et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. *J Clin Oncol* 2010;28:245-55.
  60. Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. *J Clin Oncol* 2010;28:69-76.
  61. Yao JC, Shah MH, Ito T, Lombard Bohas C, Wolin EM, et al; RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. *N Engl J Med* 2011;364:514-23.
  62. Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. *Lancet* 2016;387:968-77.
  63. Fazio N, Buzzoni R, Delle Fave G, Tesselaar ME, Wolin E, et al. Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis. *Cancer Sci* 2018;109:174-81.
  64. Lau DK, Tay RY, Yeung YH, Chionh F, Mooi J, et al. Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study. *Br J Cancer* 2018;118:966-71.
  65. Demetri GD, Chawla SP, Ray-Coquard I, Le Cesne A, Staddon AP, et al. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. *J Clin Oncol* 2013;31:2485-92.
  66. Doi T, Muro K, Boku N, Yamada Y, Nishina T, et al. Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. *J Clin Oncol* 2010;28:1904-10.
  67. Ohtsu A, Ajani JA, Bai YX, Bang YJ, Chung HC, et al. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. *J Clin Oncol* 2013;31:3935-43.
  68. O'Donnell A, Faivre S, Burris HA, Rea D, Papadimitrakopoulou V, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. *J Clin Oncol* 2008;26:1588-95.
  69. Reungwetwattana T, Molina JR, Mandrekar SJ, Allen-Ziegler K, Rowland KM, et al. Brief report: a phase II "window-of-opportunity" frontline study of the mTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study. *J Thorac Oncol* 2012;7:919-22.
  70. Besse B, Leigh N, Bennouna J, Papadimitrakopoulou VA, Blais N, et al. Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer. *Ann Oncol* 2014;25:409-15.
  71. Ng K, Taberero J, Hwang J, Bajetta E, Sharma S, et al. Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens. *Clin Cancer Res* 2013;19:3987-95.

72. Taberero J, Rojo F, Calvo E, Burris H, Judson I, et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. *J Clin Oncol* 2008;26:1603-10.
73. Spindler KL, Sorensen MM, Pallisgaard N, Andersen RF, Havelund BM, et al. Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: outcome and results of KRAS mutational analysis in plasma. *Acta Oncol* 2013;52:963-70.
74. Armstrong AJ, Shen T, Halabi S, Kemeny G, Bitting RL, et al. A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer. *Clin Genitourin Cancer* 2013;11:397-406.
75. Templeton AJ, Dutoit V, Cathomas R, Rothermundt C, Bärtzsch D, et al; Swiss Group for Clinical Cancer Research (SAKK). Phase 2 trial of single-agent everolimus in chemotherapy-naïve patients with castration-resistant prostate cancer (SAKK 08/08). *Eur Urol* 2013;64:150-8.
76. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. *Cancer Res* 2006;66:1500-8.
77. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. *J Clin Invest* 2008;118:3065-74.
78. Yu Y, Yoon SO, Poulgiannis G, Yang Q, Ma XM, et al. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signalling. *Science* 2011;332:1322-6.
79. Hsu PP, Kang SA, Rameseder J, Zhang Y, Ottina KA, et al. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signalling. *Science* 2011;332:1317-22.
80. Kim YC, Guan KL. mTOR: a pharmacologic target for autophagy regulation. *J Clin Invest* 2015;125:25-32.
81. Roux PP, Shahbazian D, Vu H, Holz MK, Cohen MS, et al. RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. *J Biol Chem* 2007;282:14056-64.
82. Sato T, Nakashima A, Guo L, Coffman K, Tamanoi F. Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer. *Oncogene* 2010;29:2746-52.
83. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. *Nature* 2013;499:43-9.
84. Wagle N, Grabiner BC, van Allen EM, Amin-Mansour A, Taylor-Weiner A, et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer. *N Engl J Med* 2014;371:1426-33.
85. Tan J, Lee PL, Li Z, Jiang X, Lim YC, et al. B55β-associated PP2A complex controls PDK1-directed myc signaling and modulates rapamycin sensitivity in colorectal cancer. *Cancer Cell* 2010;18:459-71.
86. Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. *N Engl J Med* 2012;366:883-92.
87. El-Chemaly S, Taveira-Dasilva A, Goldberg HJ, Peters E, Haughey M, et al. Sirolimus and autophagy inhibition in lymphangioleiomyomatosis: results of a phase I clinical trial. *Chest* 2017;151:1302-10.
88. Haas NB, Appleman LJ, Stein M, Redlinger M, Wilks M, et al. Autophagy inhibition to augment mTOR inhibition: a phase I/II trial of everolimus and hydroxychloroquine in patients with previously treated renal cell carcinoma. *Clin Cancer Res* 2019;25:2080-7.
89. Chi MS, Lee CY, Huang SC, Yang KL, Ko HL, et al. Double autophagy modulators reduce 2-deoxyglucose uptake in sarcoma patients. *Oncotarget* 2015;6:29808-17.
90. Schenone S, Brullo C, Musumeci F, Radi M, Botta M. ATP-competitive inhibitors of mTOR: an update. *Curr Medicin Chem* 2011;18:2995-3014.
91. Fazio N, Buzzoni R, Baudin E, Antonuzzo L, Hubner RA, et al. A phase II study of bez235 in patients with everolimus-resistant, advanced pancreatic neuroendocrine tumours. *Anticancer Res* 2016;36:713-9.
92. Rodon J, Pérez-Fidalgo A, Krop IE, Burris H, Guerrero-Zotano A, et al. Phase I/II dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer. *Cancer Chemother Pharmacol* 2018;82:285-98.
93. Britten CD, Adjei AA, Millham R, Houk BE, Borzillo G, et al. Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer. *Invest New Drugs* 2014;32:510-7.
94. Bendell JC, Varghese AM, Hyman DM, Bauer TM, Pant S, et al. A first-in-human phase I study of LY3023414, an oral PI3K/mTOR dual inhibitor, in patients with advanced cancer. *Clin Cancer Res* 2018;24:3253-62.
95. Roberts PJ, Usary JE, Darr DB, Dillon PM, Pfefferle AD, et al. Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models. *Clin Cancer Res* 2012;18:5290-303.
96. Tolcher AW, Bendell JC, Papadopoulos KP, Burris HA, Patnaik A, et al. A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors. *Ann Oncol* 2015;26:58-64.
97. Liu X, Lorusso P, Mita M, Piha-Paul S, Hong DS, et al. Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment response. *Oncologist* 2014;19:426-8.
98. Kasner MT, Mick R, Jeschke GR, Carabasi M, Filicco-O'Hara J, et al. Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition. *Invest New Drugs* 2018;36:657-66.
99. Burnett AK, Das Gupta E, Knapper S, Khwaja A, Sweeney M, et al; UK NCRI AML Study Group. Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial. *Haematologica* 2018;103:1654-61.
100. Schuetz SM, Zhao L, Chugh R, Thomas DG, Lucas DR, et al. Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma. *Eur J Cancer* 2012;48:1347-53.

101. Wood A, George S, Adra N, Chintala S, Damayanti N, et al. Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma. *Invest New Drugs* 2019; Epub ahead of print [DOI: 10.1007/s10637-019-00864-7]
102. Tew WP, Sill MW, Walker JL, Secord AA, Bonebrake AJ, et al. Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study. *Gynecol Oncol* 2018;151:257-263.
103. Sherman WH. Sirolimus can reverse resistance to gemcitabine, capecitabine and docetaxel combination therapy in pancreatic cancer. *JOP* 2009;10:393-5.
104. Lee JS, Yost SE, Blanchard S, Schmolze D, Yin HH, et al. Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer. *Breast Cancer Res* 2019;21:119.
105. Shi Y, Zhang W, Ye Y, Cheng Y, Han L, et al. Benefit of everolimus as a monotherapy for a refractory breast cancer patient bearing multiple genetic mutations in the PI3K/AKT/mTOR signaling pathway. *Cancer Biol Med* 2018;15:314-21.
106. Parachoniak CA, Rankin A, Gaffney B, Hartmaier R, Spritz D, et al. Exceptional durable response to everolimus in a patient with biphenotypic breast cancer harboring an STK11 variant. *Cold Spring Harb Mol Case Stud* 2017;3:a000778.
107. Iyer G, Hanrahan AJ, Milowsky MI, Al-Ahmadie H, Scott SN, et al. Genome sequencing identifies a basis for everolimus sensitivity. *Science* 2012;338:221.
108. Yi Z, Ma F, Liu B, Guan X, Li L, et al. Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study. *BMC Cancer* 2019;19:442.
109. Bellmunt J, Lalani AA, Jacobus S, Wankowicz SA, Polacek L, et al. Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma. *Br J Cancer* 2018;119:707-12.
110. Sharma S, Becerra CR, Matrana MR, Alistar AT, Chiorean EG, et al. A phase I/II multicenter study of ABI-009 (nab-sirolimus) combined with FOLFOX and bevacizumab as first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC) with or without PTEN loss. *J Clin Oncol* 2019;37.
111. Kwiatkowski DJ, Choueiri TK, Fay AP, Rini BI, Thorner AR, et al. Mutations in TSC1, TSC2, and MTOR are associated with response to rapalogs in patients with metastatic renal cell carcinoma. *Clin Cancer Res* 2016;22:2445-52.
112. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med* 2004;350:2129-39.
113. Juengel E, Kim D, Makarevic J, Reiter M, Tsaor I, et al. Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib. *J Cell Mol Med* 2015;19:430-41.
114. Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. *Lancet Oncol* 2015;16:1473-82.
115. Matsubara N, Naito Y, Nakano K, Fujiwara Y, Ikezawa H, et al. Lenvatinib in combination with everolimus in patients with advanced or metastatic renal cell carcinoma: a phase I study. *Int J Urol* 2018;25:922-8.
116. Hutson TE, Escudier B, Esteban E, Bjarnason GA, Lim HY, et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. *J Clin Oncol* 2014;32:760-7.
117. Zarrabi K, Fang C, Wu S. New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy. *J Hematol Oncol* 2017;10:38.
118. Paplomata E, Zelnak A, Santa-Maria CA, Liu Y, Gogineni K, et al. Use of everolimus and trastuzumab in addition to endocrine therapy in hormone-refractory metastatic breast cancer. *Clin Breast Cancer* 2019;19:188-96.
119. Bachelot T, Bourcier C, Cropet C, Ray-Coquard I, Ferrero JM, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. *J Clin Oncol* 2012;30:2718-24.
120. Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. *N Engl J Med* 2012;366:520-9.
121. Kornblum N, Zhao F, Manola J, Klein P, Ramaswamy B, et al. Randomized phase II trial of fulvestrant plus everolimus or placebo in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer resistant to aromatase inhibitor therapy: results of PrE0102. *J Clin Oncol* 2018;36:1556-63.
122. Shimoi T, Shimomura A, Shien T, Uemura Y, Kato H, et al. Open-label Phase II study of everolimus plus endocrine therapy in postmenopausal women with ER-positive and HER2-negative metastatic breast cancer (Chloe trial). *Open Access J Clin Trials* 2018;10:13-8.
123. Schmid P, Zaiss M, Harper-Wynne C, Ferreira M, Dubey S, et al. Fulvestrant plus vistusertib vs fulvestrant plus everolimus vs fulvestrant alone for women with hormone receptor-positive metastatic breast cancer: the MANTA phase 2 randomized clinical trial. *JAMA Oncol* 2019; Epub head of print [DOI: 10.1001/jamaoncol.2019.2526]
124. Yoon DH, Ryu MH, Park YS, Lee HJ, Lee C, et al. Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum. *Br J Cancer* 2012;106:1039-44.
125. Buzzoni R, Pusccheddu S, Bajetta E, De Braud F, Platania M, et al. Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study. *Ann Oncol* 2014;25:1597-603.
126. Brose MS, Troxel AB, Yarchoan M, Cohen AB, Harlackner K, et al. A phase II study of everolimus (E) and sorafenib (S) in patients (PTS) with metastatic differentiated thyroid cancer who have progressed on sorafenib alone. *J Clin Oncol* 2015;33:6072.
127. Hanna GJ, Busaidy NL, Chau NG, Wirth LJ, Barletta JA, et al. Genomic correlates of response to everolimus in aggressive radioiodine-

- refractory thyroid cancer: a phase ii study. *Clin Cancer Res* 2018;24:1546-53.
128. Wolpin BM, Ng K, Zhu AX, Abrams T, Enzinger PC, et al. Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer. *Oncologist* 2013;18:377-8.
  129. Lombard-Bohas C, Yao J, Hobday T, Van Cutsem E, Wolin E, et al. Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial. *Pancreas* 2015;44:181-9 [DOI: 10.1097/MPA.0000000000000262]
  130. Rodrik-Outmezguine VS, Okaniwa M, Yao Z, Novotny CJ, McWhirter C, et al. Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor. *Nature* 2016;534:272-6.
  131. Fan Q, Aksoy O, Wong RA, Ilkhanizadeh S, Novotny CJ, et al. A kinase inhibitor targeted to mTORC1 drives regression in glioblastoma. *Cancer Cell* 2017;31:424-35.